Exciting Development in Liver Health Monitoring
Nordic Bioscience has announced the launch of its innovative PRO-C3 test, now available through Roche Diagnostics on their advanced cobas analysers. This collaboration brings significant strides in assessing liver fibrosis severity, a condition contributing to approximately one in every 25 deaths globally.
Understanding the Importance of PRO-C3
The PRO-C3 biomarker, developed by Nordic Bioscience, represents a pivotal advancement in the realm of precision medicine. Utilizing the ADAPT formula, which includes factors like age and diabetes status alongside PRO-C3 and platelet counts, this test provides a comprehensive analysis of liver health. This allows for a more accurate determination of the severity of liver fibrosis, profoundly impacting patient management and treatment strategies.
Research Backing and Validation
Nordic Bioscience’s PRO-C3 has undergone rigorous validation within its CAP-CLIA certified laboratory, highlights the company's commitment to delivering high-quality testing solutions. The extensive research conducted by Nordic Bioscience scientists over the past decade, resulting in over 250 published scientific papers, has established the firm as a leader in studies related to PRO-C3 and fibrotic diseases.
The Need for Effective Tools
With an alarming correlation between liver-related organ changes and mortality rates — with 40% of deaths in the western world connected to such alterations — the demand for effective diagnostic tools is clearer than ever. PRO-C3 addresses this need by providing healthcare professionals with a reliable means to quantify liver health trends.
CEO Insights on the Collaboration
Morten Karsdal, CEO of Nordic Bioscience, expressed enthusiasm for the partnership with Roche Diagnostics, stating, "The Elecsys PRO-C3 test is the first test launched from the collaboration. We are proud that our technology becomes globally available to make a difference for patients." This remark underscores the potential impact of their joint efforts on improving health outcomes worldwide.
About the PRO-C3 Biomarker
The PRO-C3 test, previously available only through Nordic Bioscience's laboratory, is now set to become a standard tool for clinicians. Through its licensing agreement with Roche Diagnostics, the Elecsys PRO-C3 test will be developed and made widely accessible, marking a significant milestone in the journey toward enhanced patient care.
Nordic Bioscience: A Focus on Precision Medicine
Nordic Bioscience, headquartered in Denmark, dedicates itself to advancing biomarker technologies that facilitate rapid and precise decision-making in clinical trials and diagnostics. By incorporating unique neoepitope technology, the company is positioned to significantly enhance patient treatment pathways and contribute to the field of biomarker development.
Frequently Asked Questions
What is the PRO-C3 test?
The PRO-C3 test is a biomarker developed by Nordic Bioscience to assess the severity of liver fibrosis and aid in precision medicine.
How does the PRO-C3 test work?
It works by using the ADAPT formula, taking into account various patient factors including age, diabetes status, PRO-C3 levels, and platelet counts to evaluate liver health.
Who developed PRO-C3?
PRO-C3 was innovated by Nordic Bioscience and is now launched in collaboration with Roche Diagnostics.
Why is the PRO-C3 test significant?
This test addresses the urgent need for accurate tools in diagnosing liver fibrosis, crucial for patient management and reducing mortality rates associated with liver diseases.
What are Nordic Bioscience’s goals?
Nordic Bioscience aims to improve patient outcomes through innovative biomarker development and precision medicine strategies, enhancing clinical trial processes and diagnostics.
